IOL Chemicals and Pharmaceuticals has commenced state-of-the-art Unit-11 on March 24, 2025 for manufacturing Paracetamol at its existing location at Barnala, Punjab with an installed capacity of 10,800 MTPA. Unit-11 is supported by backward integration, with in-house production of key intermediates, Para Amino Phenol (PAP) and Acetic Anhydride, both essential for Paracetamol manufacturing.
Further, the company has enhanced the installed capacity of Unit 5 for manufacturing Clopidogrel Bisulphate from 180 MTPA to 240 MTPA on March 24, 2025 with an capital expenditure of Rs 7.87 crore funded through internal accruals.
IOL Chemicals and Pharmaceuticals is India's one of the leading generic pharmaceutical companies, and is significant player in the Organic chemicals space.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: